Norwegian Institute of Public Health, Oslo, Norway.
Eur J Clin Pharmacol. 2010 Apr;66(4):399-406. doi: 10.1007/s00228-009-0749-x. Epub 2009 Nov 21.
The purpose of this study was to examine gender- and age-specific prevalence, incidence, and the type of anti-asthma medications used in the Norwegian population aged 2-29 years during 2005-2007 and to estimate the share of individuals who regularly redeemed medications over a 3-year period.
We retrieved data from the nationwide Norwegian Prescription Database for all individuals 2-29 years old (n = 1.7 million) who received anti-asthma medications during 2005-2007. Medications included inhaled short- and long-acting beta(2)-agonists, inhaled corticosteroids, fixed-dose combinations of inhaled beta(2)-agonists and corticosteroids, and leukotriene antagonists.
In 2007, 5.5% (92,074 individuals) of Norwegians aged 2-29 years received anti-asthma medication, and this figure was stable throughout 2005-2007. Prevalence and incidence were higher among males than females but shifted to female dominance during adolescence. The share of anti-asthma medication users who received inhaled corticosteroids was high in preschool children but decreased by age. Conversely, use of inhaled beta(2)-agonists as monotherapy and of fixed combinations increased with age. Fewer than half the individuals were "persistent" to medication treatment for 3 years by redeeming prescriptions regularly (at least once a year).
In this nationwide study, annual prevalence of anti-asthma medication use was stable during 2005-2007. The gender- and age-specific profile of prevalence and incidence correspond well with other studies. Fewer than half the individuals redeemed prescriptions regularly over 3 years.
本研究旨在调查 2005-2007 年间挪威 2-29 岁人群中性别和年龄特异性哮喘药物的使用流行率、发病率和类型,并评估在 3 年内定期用药者的比例。
我们从全国性的挪威处方数据库中检索了所有在 2005-2007 年间接受过哮喘药物治疗的 2-29 岁个体(n=170 万)的数据。所使用的药物包括吸入性短效和长效β2-激动剂、吸入性皮质激素、吸入性β2-激动剂和皮质激素固定剂量联合制剂以及白三烯拮抗剂。
2007 年,5.5%(92074 人)的 2-29 岁挪威人接受了哮喘药物治疗,且这一数字在 2005-2007 年间保持稳定。与女性相比,男性的患病率和发病率更高,但在青春期后转为女性为主。接受吸入皮质激素治疗的哮喘药物使用者中,学龄前儿童的比例较高,但随年龄增长而下降。相反,单独使用吸入性β2-激动剂和使用固定联合制剂的比例随年龄增长而增加。定期(至少每年一次)取药的哮喘药物使用者中,不到一半的人坚持用药 3 年。
在这项全国性研究中,2005-2007 年间哮喘药物的年使用流行率保持稳定。患病率和发病率的性别和年龄特异性分布与其他研究相符。不到一半的人在 3 年内定期取药。